The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells.
暂无分享,去创建一个
Kun Zhang | Jessica E Young | Athurva Gore | Kun Zhang | L. Goldstein | A. Gore | Zhe Li | Jessica E. Young | Fernando J. Martinez | Shauna H. Yuan | Lawrence S B Goldstein | Floyd Buen | Grace Woodruff | Zhe Li | Fernando J Martinez | Floyd Buen | Jennifer Kinaga | Shauna H Yuan | J. Kinaga | G. Woodruff
[1] Y. Ihara,et al. Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. , 2003, The Journal of biological chemistry.
[2] Alisa Opar. Mixed results for disease-modification strategies for Alzheimer's disease , 2008, Nature Reviews Drug Discovery.
[3] R. J. Kelleher,et al. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.
[4] D. Borchelt,et al. Effects of PS1 Deficiency on Membrane Protein Trafficking in Neurons , 1998, Neuron.
[5] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[6] L. Goldstein,et al. Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects. , 2012, Human molecular genetics.
[7] M. Adams,et al. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene , 1995, Neuroreport.
[8] E. Kandel,et al. Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration , 2004, Neuron.
[9] William J. Ray,et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.
[10] Huaxi Xu,et al. Presenilin 1 Is Required for Maturation and Cell Surface Accumulation of Nicastrin* , 2002, The Journal of Biological Chemistry.
[11] E. Kirkness,et al. Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.
[12] M. Goedert,et al. The value of incomplete mouse models of Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[13] K. Zahs,et al. Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.
[14] J. Mertens,et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. , 2012, The American journal of pathology.
[15] B. Strooper,et al. Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.
[16] K. Yaffe,et al. The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.
[17] R. Stewart,et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells , 2011, Nature.
[18] D. Westaway,et al. Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.
[19] S. Orkin,et al. A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome , 2012, Science Translational Medicine.
[20] R. J. Kelleher,et al. A Presenilin-1 Mutation Identified in Familial Alzheimer Disease with Cotton Wool Plaques Causes a Nearly Complete Loss of γ-Secretase Activity* , 2010, The Journal of Biological Chemistry.
[21] M. Tomishima,et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.
[22] Kerry A. Mullaney,et al. Alzheimer’s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition , 2009, Proceedings of the National Academy of Sciences.
[23] C. van Broeckhoven,et al. Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.
[24] Sooyeon Lee,et al. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification , 2013, The European journal of neuroscience.
[25] A. Extance. Alzheimer's failure raises questions about disease-modifying strategies , 2010, Nature Reviews Drug Discovery.
[26] B. de Strooper,et al. The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.
[27] Hugo Vanderstichele,et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.
[28] F. Gage,et al. Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells , 2011, PloS one.
[29] Shondra M Pruett-Miller,et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases , 2011, Nature Methods.
[30] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[31] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[32] Susan Lindquist,et al. Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.
[33] Kevin Kim,et al. A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.
[34] Timothy B. Stockwell,et al. The Diploid Genome Sequence of an Individual Human , 2007, PLoS biology.
[35] Riitta Lahesmaa,et al. Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.
[36] S. Tonegawa,et al. Skeletal and CNS Defects in Presenilin-1-Deficient Mice , 1997, Cell.
[37] H. Okano,et al. [Modeling familial Alzheimer's disease with induced pluripotent stem cells]. , 2012, Rinsho shinkeigaku = Clinical neurology.
[38] P. Schofield,et al. Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques , 2004, Neurobiology of Disease.
[39] J. Regula,et al. Reconstitution of γ-secretase activity , 2003, Nature Cell Biology.
[40] Elo Leung,et al. A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.
[41] Kristopher L. Nazor,et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.
[42] S. Angulo,et al. Retraction Notice to: Directed Conversion of Alzheimer’s Disease Patient Skin Fibroblasts into Functional Neurons , 2014, Cell.
[43] H. Soininen,et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[44] D. Borchelt,et al. Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo , 1996, Neuron.
[45] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[46] T. Ichisaka,et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.
[47] J. Keith Joung,et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs , 2011, Nature Biotechnology.
[48] J. Hardy,et al. Antisense‐Induced Reduction of Presenilin 1 Expression Selectively Increases the Production of Amyloid β42 in Transfected Cells , 1999, Journal of neurochemistry.
[49] Y. Ihara,et al. Potential Link between Amyloid β-Protein 42 and C-terminal Fragment γ 49–99 of β-Amyloid Precursor Protein* , 2003, Journal of Biological Chemistry.
[50] A. Levey,et al. Presenilin 1 Independently Regulates β-Catenin Stability and Transcriptional Activity* , 2001, The Journal of Biological Chemistry.
[51] D. Campion,et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.
[52] J. Regula,et al. Reconstitution of gamma-secretase activity. , 2003, Nature cell biology.